Prospective Multicenter Observational Study of Anlotinib in Advanced Non‐Small Cell Lung Cancer: Real‐World Evidence From China

ABSTRACT Background Anlotinib has shown remarkable efficacy in later‐line treatment of advanced non‐small cell lung cancer (NSCLC). This prospective real‐world study evaluated its efficacy and safety in routine clinical practice. Methods Patients from 13 centers in China received anlotinib (8–12 mg)...

Descrición completa

Detalles Bibliográficos

Principais autores:	Jinlin Wang, Youhong Dong, Fengjun Cao, Ruizhi Ran, Yifa Yin, Yinping Li, Yang Fu, Yanhua Xu, Li Kuang, Guiming Chen, Guangqiao Qu, Jun Li, Zhiguo Luo, Qibin Song, Yuan Chen, Xinhua Xu, Tienan Yi, Qian Chu
Formato:	Artigo
Idioma:	Inglês
Publicado:	Wiley 2026-06-01
Series:	Thoracic Cancer
Assuntos:	advanced NSCLC anlotinib efficacy prospective real‐world study safety
Acceso en liña:	https://doi.org/10.1111/1759-7714.70306
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!